Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical company Dechra Pharmaceuticals said it expected full-year revenue to be ahead of current market expectations amid ongoing momentum.
The company said was increasingly confident that this strong performance would continue for the rest of this financial year, in the wake of the momentum coupled with the completion of the UK pre-Brexit inventory unwind and the further easing of lockdown restrictions.
The strong performance reported for the first seven months of the current financial year, had continued to benefit from 'strong market fundamentals as well as lower underlying selling, general and administration costs as a result of COVID-19,' the company said.
'Trading was likely to be distributed more evenly than previously guided between the first and second halves of the financial year,' it added.